Monte Rosa Therapeutics (GLUE) Superinvestor holders
9 of the superinvestors we track hold Monte Rosa Therapeutics (GLUE) in their latest 13F filings, $88M in total.
Summary
The largest holder is Paul Marshall (Marshall Wace), with $39M, 0.0% of the portfolio.
In their latest quarter: 2 opened a new position, 3 added, 3 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Paul Marshall Marshall Wace |
Added | 1,593,600 | $39M | 0.0% | Q2 2026 |
| Wilmot Harkey Nantahala Capital Management |
Held | 651,993 | $16M | 1.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 520,648 | $13M | 0.0% | Q2 2026 |
| Stanley Druckenmiller Duquesne Family Office |
New position | 297,600 | $7M | 0.2% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 172,053 | $4M | 0.0% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 295,844 | $4M | 0.0% | Q3 2026 |
| Two Sigma Two Sigma Investments |
Added | 140,923 | $3M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 102,500 | $2M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
New position | 2,625 | $31,000 | 0.0% | Q3 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 8 |
| Q1 2026 | 10 |
| Q4 2025 | 10 |
| Q3 2025 | 10 |
| Q2 2025 | 8 |
| Q1 2025 | 7 |
| Q4 2024 | 5 |
| Q3 2024 | 5 |
Questions about Monte Rosa Therapeutics
Which superinvestors own Monte Rosa Therapeutics?
9 of the superinvestors we track hold Monte Rosa Therapeutics (GLUE) in their latest 13F filings, $88M in total. Paul Marshall, Wilmot Harkey, Cliff Asness, Stanley Druckenmiller, David Shaw, Ken Fisher.
Who is the largest superinvestor holder of GLUE?
The largest holder is Paul Marshall (Marshall Wace), with $39M, 0.0% of the portfolio.
From Monte Rosa Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.